Page last updated: 2024-10-29

ketanserin and Erythrocytosis

ketanserin has been researched along with Erythrocytosis in 1 studies

Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Borawski, J1
Mazerska, M1
Rydzewski, A1
Pawlak, K1
Rowinski, M1
Mysliwiec, M1

Trials

1 trial available for ketanserin and Erythrocytosis

ArticleYear
Ketanserin: a new perspective in posttransplant erythrocytosis?
    Clinical transplantation, 1996, Volume: 10, Issue:1 Pt 1

    Topics: Adult; Erythropoietin; Humans; Ketanserin; Kidney Transplantation; Male; Middle Aged; Polycythemia;

1996